Additional file 1: of Mutations in the MTHFR gene are not associated with Methotrexate intolerance in patients with juvenile idiopathic arthritis

Table S3. Demographic and clinical data of study participants; patients where MTHFR testing was available. Table S4. Influence of demographic and clinical data on MTX intolerance; patients where MTHFR testing was available. (DOCX 35 kb

Additional file 1: Table S1. of Urine S100 proteins as potential biomarkers of lupus nephritis activity

Demographic and clinical data on patients with cSLE with unpaired serum and urine samples from Cohorts Xs and Xu. (DOCX 17 kb

Additional file 2: Table S2. of Urine S100 proteins as potential biomarkers of lupus nephritis activity

Median S100 and laboratory values in patients with cSLE from Cohorts Ls and Lu. (DOCX 14 kb

Additional file 1: of Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study

Inclusion criteria for the long-term extension study, dosing scheme, and descriptive summary of plasma tofacitinib pharmacokinetic parameter values by gender. (PDF 39 kb

Additional file 1: of Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy

Table S1 Definition of adapted ACR JIA response. Table S2 Genes with ≥3-fold differential expression between patients with SJIA and healthy controls, prior to canakinumab treatment. Table S3 List of independent ethics committees or institutional review boards (trial 1). Table S4 List of independent ethics committees or institutional review boards (trial 2). (DOCX 53 kb